A Phase II, Multicenter, Single-Arm, Two-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Patients With Advanced Basal Cell Carcinoma.

Trial Profile

A Phase II, Multicenter, Single-Arm, Two-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Patients With Advanced Basal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ERIVANCE BCC
  • Sponsors Genentech
  • Most Recent Events

    • 02 Aug 2017 Results of pooled retrospective analysis of this and other 3 studies published in the Journal of the American Academy of Dermatology.
    • 25 May 2016 Results assessing effectiveness of the two drugs using a matching-adjusted indirect comparison from BOLT and ERIVANCE trials presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 01 Jun 2015 Results published in the Journal of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top